Boston Scientific Corporation $BSX Position Decreased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its holdings in Boston Scientific Corporation (NYSE:BSX) by 1.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 169,986 shares of the medical equipment provider’s stock after selling 1,783 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Boston Scientific were worth $18,258,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Sound Income Strategies LLC increased its holdings in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares in the last quarter. 1248 Management LLC acquired a new position in shares of Boston Scientific in the 1st quarter worth $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific in the 1st quarter worth $27,000. Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Boston Scientific during the second quarter worth $37,000. Finally, Activest Wealth Management lifted its holdings in shares of Boston Scientific by 6,216.7% during the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 373 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Up 1.5%

Boston Scientific stock opened at $99.20 on Friday. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a market cap of $146.99 billion, a PE ratio of 59.05, a P/E/G ratio of 2.39 and a beta of 0.61. The firm’s 50 day moving average price is $101.29 and its two-hundred day moving average price is $101.75.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the company posted $0.62 EPS. Boston Scientific’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the topic of several recent analyst reports. Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 11th. Robert W. Baird upped their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, BTIG Research boosted their target price on shares of Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $120.71.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.